T-Cypher Bio expands into purpose-built laboratory space at Abingdon Science Park
Oxford-based biotechnology company T-Cypher Bio has relocated its headquarters to a newly built 12,000 sq ft facility at Abingdon Science Park, providing additional laboratory capacity as it advances its pipeline of T cell engager therapies.
T-Cypher Bio, a biotechnology company developing T cell receptor (TCR)-based T cell engagers, has moved into purpose-built laboratory and office space at Barton House, Abingdon Science Park, Oxford.
The new facility, developed by science property specialist Kadans Science Partner, will support the company's continued growth and progression of its therapeutic pipeline, which targets areas of high unmet need in solid tumours and autoimmune disease.
The 12,000 sq ft facility includes Containment Level 2 wet laboratories and open-plan office space, with specialist infrastructure designed around T-Cypher's research and operational requirements. The expansion provides additional tissue culture capacity to support the company's in-vitro research and preparation for Investigational New Drug (IND)-enabling studies.
Advancing T cell engager research
Founded as a deep tech company, T-Cypher has developed an integrated discovery platform combining computational and laboratory-based systems to investigate human disease targets and their associated T cell reactivity.
Its proprietary platform, T-C Alpha (T-Ca), incorporates a machine-learning engine designed to profile the human disease target space, identify high copy number antigens and support the development of next-generation TCR-based therapeutics.
The company is developing immune engager treatments for solid tumours and autoimmune conditions, with its new laboratory environment intended to accommodate the research requirements as these programmes progress towards clinical development.
Sarah Leonard, Chief Executive Officer of T-Cypher Bio, said:
“Moving to Barton House allowed the expansion of our tissue culture space, critical to the in-vitro work needed for our IND-enabling studies, as we progress towards the clinic. Working with Kadans has allowed us to be involved in the design process from the start, ensuring the new space meets our requirements and enabling a seamless transition between sites with minimal disruption to our research activities.”
Supporting Oxford's life sciences ecosystem
Abingdon Science Park is a 500,000 sq ft life sciences and innovation campus within the Oxford ecosystem. Its existing occupiers include Penlon, Alethio Therapeutics, Sense Bio and Capgemini.
The Barton House development provides T-Cypher with access to specialist laboratory infrastructure alongside the wider network of organisations operating across the campus and Oxfordshire's life sciences sector. Kadans also offers access to its wider European life sciences network, with opportunities for collaboration and knowledge-sharing.
Leonard added: “We have been impressed throughout by both the quality and speed of the fit-out; the expertise and responsiveness of the Kadans team has been instrumental in creating a laboratory environment completely tailored to our scientific needs. Settling into our new home on Abingdon Science Park is an exciting milestone as we look ahead to the future of our company and its vision for building next gen-TCR-based bispecifics in oncology and autoimmune disease.”
Katie Nelson, Head of Leasing UK&I at Kadans Science Partner, said the facility had been developed in collaboration with T-Cypher to accommodate its specialist laboratory requirements.
“By involving the team throughout the design and delivery process, we were able to create a purpose-built space including specialist labs tailored exactly to the Company. This project demonstrates how Kadans works with scientific organisations through every step of the process. We are proud to welcome another transformative company to our community and be part of T-Cypher’s growth in this way.”
The relocation marks a further addition to Oxford's life sciences infrastructure, with Abingdon Science Park continuing to offer laboratory and innovation-led space ranging from 1,100 sq ft to 21,148 sq ft.
Author
BioFocus Newsroom